Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients

BACKGROUND: Bevacizumab combined with chemotherapy produces clinical durable response in 25–30% of recurrent glioblastoma patients. This group of patients has shown improved survival and quality of life. The aim of this study was to investigate changes in gene expression associated with response and...

Descripción completa

Detalles Bibliográficos
Autores principales: Urup, Thomas, Staunstrup, Line Mærsk, Michaelsen, Signe Regner, Vitting-Seerup, Kristoffer, Bennedbæk, Marc, Toft, Anders, Olsen, Lars Rønn, Jønson, Lars, Issazadeh-Navikas, Shohreh, Broholm, Helle, Hamerlik, Petra, Poulsen, Hans Skovgaard, Lassen, Ulrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395849/
https://www.ncbi.nlm.nih.gov/pubmed/28420326
http://dx.doi.org/10.1186/s12885-017-3251-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395849/
https://www.ncbi.nlm.nih.gov/pubmed/28420326
http://dx.doi.org/10.1186/s12885-017-3251-3

Ejemplares similares